Phase II Trial of Rituximab Plus 2CdA [cladribine] in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT).
Phase of Trial: Phase II
Latest Information Update: 24 Apr 2014
At a glance
- Drugs Rituximab (Primary) ; Cladribine
- Indications Marginal-zone-B-cell-lymphoma
- Focus Therapeutic Use
- 26 Nov 2013 Treatment table added.
- 21 Jun 2011 Planned end date changed from 1 Dec 2010 to 1 Dec 2011 as reported by ClinicalTrials.gov.
- 21 Jun 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.